SELECT PUBLICATIONS

Albain K. Overall survival after cyclophosphamide, adriamycin, 5-FU and tamoxifen (CAFT) is superior to T alone in post-menopausal, receptor(+), node(+) breast cancer: New findings from phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100). Proc ASCO 2001;Abstract 94.

Baum M et al. Management of premenopausal women with early breast cancer: Is there a role for goserelin? Proc ASCO 2001; Abstract 103.

Boccardo F et al. Cyclophosphamide, methotrexate and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000;18:2718-27. Abstract

Buchholz TA et al. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol 2001;19(8):2240-6. Abstract

Cauley JA et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65(2):125-34. Abstract

Cheung KL et al. The combined use of goserelin and anastrozole as second-line endocrine therapy in premenopausal women with advanced breast cancer — a study of its clinical and endocrine effects. Proc ASCO 2001;Abstract 1937.

Chlebowski RT et al. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene. J Clin Oncol 1999;17(6):1939-55. Abstract

Davidson N et al. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III Intergroup trial (E5188, INT-0101). Proc ASCO 1999;Abstract 249A, 67A.

Day et al. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17(9):2659-69. Abstract

de Haes H et al. Early benefits in quality of life (QoL) observed in zoladex-treated versus CMF-treated pre-/perimenopausal patients with node-positive early breast cancer. Proc ASCO 2001; Abstract 138.

Demissie S et al. Adjuvant tamoxifen: Predictors of use, side effects and discontinuation in older women. J Clin Oncol 2001;19:322-8. Abstract

Fallowfield L et al. Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 2001;19:1885-92. Abstract

Fisher B et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93(9):684-90. Abstract

Fisher B et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001;93(2):112-20. Abstract

Fisher B et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90(18):1371-88. Abstract

Forward D et al. Combined use of goserelin (Zoladex) and anastrozole (Arimidex) in premenopausal women with metastatic breast cancer (MBC). Proc ASCO 2000; Abstract 582.

Gail MH et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91(21):1829-46. Abstract

Ganz PA et al. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 1998;152:396-411. Abstract

Henderson IC. Ovarian ablation comes around again. Breast Diseases: A Year Book Quarterly 2000;11(2):117-120. No Abstract Available

Hoffken K, Kath R. The role of LH-RH analogues in the adjuvant and palliative treatment of breast cancer. Recent Results Cancer Res 2000;153:61-70. Abstract

Houghton J et al. The ZIPP trial of adjuvant zoladex in premenopausal patients with early breast cancer: An update at five years. Proc ASCO 2000;Abstract 359.

Ingle JN et al. Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer. Endocr Relat Cancer 1999;6:265-9. Full Text

Jakesz R. Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5. Proc ASCO 1999;Abstract 250.

Li CI et al. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 2001;93(13):1008-13. Abstract

Michaud LB, Buzdar AU. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. Drugs Aging. 2000;16:261-71. Abstract

Nystedt M et al. Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer — self-rated physiological effects and symptoms. Acta Oncol 2000;39(8):959-68. Abstract

O'Reagan RM et al. Effect of raloxifene after tamoxifen on breast and endometrial cancer growth. Proc ASCO 2001;Abstract 95.

O'Regan RM, Jordan VC. Tamoxifen to raloxifene and beyond. Semin Oncol 2001;28(3):260-73. Abstract

Rockhill B et al. Validation of the Gail et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93(5):358-66. Abstract

Rutqvist LE. Zoladex ® and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomised trial by the Cancer Research Campaign (C. R. C.) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, The South-East Sweden Breast Cancer Group & the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G. I. V. I. O). Proc ASCO 1999;Abstract

251. Stewart HJ et al. Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years. J Natl Cancer Inst 2001;93(6):456-62. Abstract

Sverrisdottir A et al. Bone mineral density in premenopausal patients in a randomized trial of adjuvant endocrine therapy (ZIPP-TRIAL). Proc ASCO 2001;Abstract 96.

Wickerham DL, Tan-Chiu E. Breast cancer chemoprevention: Current status and future directions. Semin Oncol 2001;28(3):253-9. Abstract

Top

Additional Sections:
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |

Additional Sections: